(Q102058897)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

title

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

main subject

lymphoblastic leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Orietta Spinelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Erika Borlenghi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Massimo Bernardi

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Alessandro Rambaldi

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

17

Fabio Ciceri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

author name string

Chiara Pavoni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Tamara Intermesoli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Manuela Tosi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Ernesta Audisio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Filippo Marmont

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Chiara Cattaneo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Sergio Cortelazzo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Irene Cavattoni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Monica Fumagalli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Daniele Mattei

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Claudio Romani

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Agostino Cortelezzi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Nicola Fracchiolla

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Anna Maria Scattolin

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Lorella Depaoli

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Arianna Masciulli

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

Elena Oldani

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

publication date

13 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

page(s)

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

Modern therapy of acute lymphoblastic leukemia

18 November 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the P

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

How I treat acute lymphoblastic leukemia in older adolescents and young adults

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Treating childhood acute lymphoblastic leukemia without cranial irradiation

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FS41408-020-00383-2

7 January 2021

10.1038/S41408-020-00383-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33188164%20AND%20SRC:MED&resulttype=core&format=json

18 November 2020

0 references

1 reference